Pfizer Appoints Cecile Guegan as Interim CFO as Dave Denton Departs for Consumer Goods Role
核心洞察
Pfizer named Cecile Guegan, Senior Vice President of Finance for the Global Biopharmaceutical Business, as Interim CFO effective August 16, 2025.
Dave Denton stepped down on August 15 to accept a professional opportunity outside the pharmaceutical industry in consumer goods.
Guegan brings more than two decades of Pfizer experience, including leading the integration of Seagen into Pfizer in 2024.
Pfizer has appointed Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer (CFO), effective 16 August. The move follows the departure of Dave Denton, Executive Vice President and CFO, who stepped down from his role on 15 August to pursue a professional opportunity outside the pharmaceutical industry in consumer goods.
Denton and Guegan will work together to ensure a seamless transition while Pfizer conducts a comprehensive internal and external search for a permanent successor.
Leadership Transition and Experience
Guegan brings more than two decades of experience at Pfizer, amassing deep global financial experience leading finance across a wide range of complex and strategic portfolios, research and development, and several regions. In her current role, she is directly responsible for the financial operations and reporting of Pfizer's biopharmaceutical business across all therapeutic areas and geographies.
Pfizer highlighted that Guegan has strong financial judgement and a proven track record of leading important enterprise initiatives, including the integration of Seagen into Pfizer in 2024.
Albert Bourla, Chairman and CEO at Pfizer, said: "Given Cecile's deep institutional knowledge and financial acumen, I have every confidence in her ability to lead Pfizer's finance organisation and keep us focused on what matters most – executing our strategy and delivering for patients and shareholders."
Denton's Tenure and Departure
Bourla described Denton's impact on Pfizer's business journey, stating: "Dave has been a steady and trusted steward of Pfizer's financial health, and we are grateful for his leadership, especially during some of the most important business transactions in our recent history, including Seagen, Biohaven (搜索), and Metsera, that will serve Pfizer well for years to come."
Denton said: "It has been an honour and a privilege to work alongside Albert. Pfizer is in excellent hands, and I leave knowing the executive leadership team, now including Cecile as interim CFO, will continue to succeed and carry its important work forward."
Pfizer stated that Denton's departure was not related to financial or operating results or any disagreements with the company on financial, operational, accounting, or reporting policies or practices. Denton's 2025 compensation totaled $9.67 million, which included a $1.38 million salary.
Strategic Context
Pfizer expanded its offerings through acquisitions during Denton's tenure. One key acquisition was the purchase of Seagen and its cancer medicines for approximately $43 billion in 2023. The company also reduced spending and decreased staff to adjust to lower demand for its COVID offerings.
In the first quarter of 2026, Pfizer's oncology drugs Padcev and Lorbrena performed strongly.